Press Releases

PTC Therapeutics, Inc. is committed to serving the interests of all our stakeholders.
Danya
Duchenne Muscular Dystrophy, Ukraine
DANYA - Duchenne Muscular Dysthropy- Ukraine

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.


Date Title and Summary View
Feb 07, 2023 PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
SOUTH PLAINFIELD, N.J. , Feb. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2022 financial results and provide an update on the company's business and outlook on Tuesday,
Feb 03, 2023 PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
- This award recognizes PTC's 25-year legacy in discovering and delivering novel therapies that address the underlying cause of rare diseases - SOUTH PLAINFIELD, N.J. , Feb. 3, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of
Feb 02, 2023 PTC Therapeutics to Participate at Upcoming Investor Conference
SOUTH PLAINFIELD, N.J. , Feb. 2, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference:     SVB Securities Global Biopharma Conference Tuesday, Feb. 14 at 9:20 a.m.
Jan 19, 2023 NICE Recommends Reimbursement for Translarna™
- Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J. , Jan. 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final
Jan 17, 2023 PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community
- 2023 Program to Focus on Innovation and Transition to Adulthood Initiatives – - Submissions Due March 17, 2023 - SOUTH PLAINFIELD, N.J. , Jan. 17, 2023 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced the launch of the ninth annual STRIVE™ awards program.
Jan 11, 2023 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Jan. 11, 2023 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023 , the company approved non-statutory stock options to purchase an aggregate of 39,585 shares of its common stock and 13,045 restricted stock units ("RSUs"), each
Jan 09, 2023 PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference
-  ~$710 million unaudited 2022 total revenue, representing an impressive over 30% year-over-year growth – -  $940 million - $1.0 billion 2023 total revenue guidance – -  Results from three registration-directed clinical trials expected in 2023 – -  One additional registration-directed clinical
Jan 04, 2023 PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference
SOUTH PLAINFIELD, N.J. , Jan. 4, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, Jan. 9 , at 7:30 a.m. PST / 10:30 a.m. EST .
Dec 01, 2022 Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy
- First global regulatory approval for treatment of this rare genetic disease - SOUTH PLAINFIELD, N.J. , Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency , ANVISA (Agência Nacional de Vigilância Sanitária), has approved
Nov 17, 2022 Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
- Upstaza ™  is the first gene therapy infused directly into the brain for the treatment of AADC deficiency - - MHRA authorization follows recent European Union authorization - - AADC deficiency is a rare, fatal disorder that arrests motor development causing severe disability - SOUTH PLAINFIELD,